Nov. 19, 2013
/PRNewswire/ -- Tandem Diabetes Care
, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the t:slim
Insulin Pump, today announced the closing of its initial public offering of 9,200,000 shares of common stock at a price of
per share, which includes the exercise in full by the underwriters of their option to purchase up to an additional 1,200,000 shares. All of the shares in the offering were offered by Tandem. Tandem's common stock is listed on the NASDAQ Global Market under the ticker symbol "TNDM."
BofA Merrill Lynch and
acted as joint book-running managers for the offering. Deutsche Bank Securities and Stifel acted as co-managers.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission (SEC) on
November 13, 2013
. A copy of the final prospectus relating to the offering may be obtained from: BofA Merrill Lynch, 222 Broadway,
, NY 10038 Attention: Prospectus Department, by email at
& Co., Attention: Equity Capital Markets, 800 Nicollet Mall, J12S03,
55402, via telephone at 800-747-3924 or by email at
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. is a medical device company with an innovative, user-centric and integrated approach to the design, development and commercialization of products for people with insulin-dependent diabetes. The Company manufactures and sells the t:slim Insulin Pump, the slimmest and smallest durable insulin pump currently on the market, and the first and only insulin pump with a high resolution, color touch screen. Tandem is based in
San Diego, California
SOURCE Tandem Diabetes Care, Inc.